Table 1 Results of the consensus workshop for the relative importance of the evaluation criteria and their weight in the final score for each option. *The initially determined weights were refined after the case study experience by reducing the weight of the price criterion. ** Health economic or health outcomes data
Criterion | Measures | Ranking | Initial Weights* | Final Weights* |
|---|---|---|---|---|
Savings versus originator | Quantitative | Primary | 42.5% | 35.0% |
Equivalence with the reference product | Qualitative | 1 | 14.3% | 16.2% |
Stability and drug formulation | Qualitative | 2 | 11.9% | 13.5% |
Quality assurance | Qualitative | 3 | 9.9% | 11.2% |
Reliability of drug supply | Qualitative | 4 | 7.8% | 8.8% |
Macroeconomic benefit | Qualitative | 5 | 4.9% | 5.5% |
Real world outcomes** | Qualitative | 6 | 3.7% | 4.2% |
Pharmacovigilance | Qualitative | 7 | 2.9% | 3.3% |
Added value service related to product | Qualitative | 8 | 2.1% | 2.3% |